Four major receptor families enable cells to respond to chemical and physical signals from their proximal environment. The ligand-and voltage-gated ion channels, G-protein-coupled receptors, nuclear hormone receptors, and receptor tyrosine kinases are all allosteric proteins that carry multiple, spatially distinct, yet conformationally linked ligand-binding sites. Recent studies point to common mechanisms governing the allosteric transitions of these receptors, including the impact of oligomerization, pre-existing and functionally distinct conformational ensembles, intrinsically disordered regions, and the occurrence of allosteric modulatory sites. Importantly, synthetic allosteric modulators are being discovered for these receptors, providing an enriched, yet challenging, landscape for novel therapeutics.
Introduction
One of the most important concepts in the biological sciences is the notion of the receptor, or ''receptive substance,'' enunciated at the turn of the 20 th century by John Newport Langley in physiology and Paul Ehrlich in immunology. However, it took more than half a century to biochemically identify and discover the structure and dynamics of these receptor molecules and to critically evaluate the role they play in the physiology of the organism, in particular the brain (Changeux, 1990) . About 2% of the human genome encodes these receptors, which behave as the effective targets of nearly 60% of the medicines currently used in clinical practice. These essential cybernetic sensors recognize chemical signals (such as neurotransmitters, hormones, odorants, and metabolites) and physical signals (including temperature, electric fields, and physical stress), and transduce them into a cellular response. They include four major superfamilies of proteins, namely: the ligand-gated (LGICs) and voltage-gated ion channels (VGICs), the G-protein-coupled receptors (GPCRs), the nuclear hormone receptors (NHRs), and the receptor tyrosine kinases (RTKs). With the exception of the VGICs, which utilize physical activators such as voltage or temperature, the remaining canonical receptors utilize chemical messengers as the initiators of signal transduction. Given the fact that receptors are the preeminent mediators of inter-cellular communication, they are also involved in numerous diseases spanning neurological disorders, cancers, and cardiovascular, endocrinological, metabolic, and inflammatory diseases. Signal transduction mediated by receptors involves, at the molecular level, a ''communication over a distance'' between the activating site and the locus of the biological response. An important conceptual advance was thus the proposal that the mechanism linking the activating and response sites is allosteric. Typically, an allosteric interaction (Changeux, 1961; Monod and Jacob, 1961) is defined as an indirect interaction between topographically distinct (non-overlapping) binding sites mediated by a discrete, reversible, conformational change in the protein structure referred to as the allosteric transition (Figure 1) . Moreover, many regulatory proteins function as discrete ''cybernetic switches'' exhibiting cooperative binding interactions with and between substrates and regulatory ligands. To account for this characteristic feature, it was proposed that allosteric proteins are organized into symmetrical oligomers that undergo, spontaneously, discrete cooperative changes of quaternary structure between a minimum of two states that pre-exist in equilibrium to ligand binding-summarized conceptually and in terms of thermodynamic linkages in Figure 1B (top, middle). The signal transduction mechanism would then operate through the selective stabilization of the particular state to which any ligand preferentially binds and is referred to as the ''Monod-WymanChangeux'' (MWC) model (Monod et al., 1965) . Subsequently, Koshland, Nemethy, and Filmer (Koshland et al., 1966) proposed a sequential induced-fit mechanism of the allosteric transition (''KNF'' model), which involves a progressive change of conformation that excludes any conformational change of the protein in the absence of ligand. Although some debate remains about the two models, studies carried out with a large diversity of proteins have lent support to, and further extended, the MWC model, emphasizing in particular ''population shifts'' of discrete conformations within an energy landscape formalism (see Cui and Karplus, 2008; Changeux, 2013a; Horst et al., 2013; Motlagh et al., 2014; Tsai and Nussinov, 2014; Figure 1B, bottom) .
The application of the MWC concept to membrane receptors, specifically neurotransmitter receptors (Changeux, 1965; Changeux et al., 1967; Karlin, 1967) , considerably broadened its impact (Changeux, 1990) . From a pharmacological viewpoint (Figure 1A ), receptors can thus be conceived as possessing three key binding loci, all of which are linked in an allosteric manner. These are (1) the orthosteric site for endogenous or synthetic agonists, competitive antagonists, and physical signals; (2) the biologically active site, which includes the channel pore for LGICs/VGICs; the G-protein-binding site for GPCRs; the tyrosine kinase domain of RTKs; the DNA response element for NHRs; and (3) more recently discovered allosteric modulatory sites, which are topographically distinct from the above mentioned sites (Changeux, 2012 (Changeux, , 2013b Christopoulos, 2002; Christopoulos et al., 2014) . In this Review, we examine recent advances in understanding the mechanisms governing the allosteric transitions of these receptors, including the impact of oligomerization, of pre-existing and functionally distinct conformational ensembles, a role for intrinsically disordered regions, and the occurrence of allosteric modulatory sites and their important pharmacological applications.
Oligomeric versus Monomeric Organization of Receptors
While receptor families share fundamental regulatory features, they are structurally distinct ( Figure 2 ). The original MWC formulation relates the cooperative behavior of regulatory proteins to their oligomeric organization. Recent advances in structural biology have revealed the functional architectures of many receptor families, disclosing their oligomeric organization. Yet, examples of monomeric proteins showing functionally important allosteric effects have been also highlighted (Cui and Karplus, 2008) , especially in GPCRs (Canals et al., 2011) . Moreover, receptor oligomers are frequently made up of homologous subunits encoded by different genes, thus introducing pseudo-symmetry in their multiple assemblies.
The major subgroup of the LGICs (Figure 2A ; 76 members in the human genome) first consists of the pentameric ligand gated ion channels (pLGICs) , which include the stimulatory nicotinic acetylcholine receptors (nAChRs) and serotonin (5HT 3 ) and the inhibitory glycine, glutamate, and GABA A receptors; second, the tetrameric ionotropic glutamate receptors (NMDA, AMPA, kainate); and third, the trimeric ATP-gated P2X receptors and acid-sensing channels (Baconguis et al., 2013) . Although some LGICs exist as homomeric assemblies, the majority are hetero-oligomers comprising different subunits that share a common architecture.
All pLGIC subunits consist of a large hydrophilic amino-terminal extracellular domain (ECD), a transmembrane (TM) domain Changeux (1961) . Right: schematic summarizing the key conformationally linked sites common to all receptor superfamilies, namely the ''orthosteric site,'' which recognizes the endogenous agonist or physical activator, the ''biologically active site,'' which propagates the initial stimulus imparted by the orthosteric ligand and one (or more) topographically distinct ''allosteric sites'' that modulate the interactive properties of the orthosteric and/or active sites via discrete conformational changes. (B) Schematic representations of the original Monod-Wyman-Changeux concerted model of allostery in terms of a minimum of two discrete, pre-existing states in equilibrium, ''relaxed'' (R) and ''tense'' (T), that can be differentially selected by various ligands. The three classes of molecules in the original conceptual model (top) were ''activator'' (A), ''substrate'' (S), and ''inhibitor'' (I) (from Changeux, 1964 ). The cubic model underneath re-casts the MWC model in terms of thermodynamic equilibrium linkages comprising unconditional isomerization (L) or dissociation constants (K A , K S ), and cooperativity factors (a, b, g, d) , which yield conditional dissociation constants and are direct thermodynamic measures of the allosteric linkage governing the different transitions (Christopoulos and Kenakin, 2002; Edelstein and Changeux, 2010 (TMD) comprising four hydrophobic segments (M1-M4), and a variable hydrophilic cytoplasmic or intracellular (IC) domain (ICD), which is absent in prokaryotic pLGICs. Complete atomic structures of homomeric pLGICs have been obtained for two prokaryotic receptors from Gloeobacter violaceus (GLIC) (Bocquet et al., 2009) and Erwinia chrysanthemi (ELIC) (Hilf and Dutzler, 2008) and for four eukaryotic receptors: GluCl from Caenorhabditis elegans (Hibbs and Gouaux, 2011) , the 5HT 3 receptor from mouse (Hassaine et al., 2014) , a human homopentameric b 3 GABA A receptor (Miller and Aricescu, 2014) , and the glycine receptor from zebrafish (Du et al., 2015) . Overall, the available structures of prokaryotic and eukaryotic pLGICs reveal strikingly similar 3D oligomeric arrangements with a 5-fold axis of symmetry perpendicular to the membrane plane. Available structural data from the ACh binding protein (AChBP), GLIC, ELIC, GluCl, and GABA A validate the location of the orthosteric binding site in the ECD at the interface between subunits from three regions of a ''principal'' subunit (loops A, B, and C) and four from a ''complementary'' subunit (loops D, E, F, and G) (Cecchini and Changeux, 2015; Corringer et al., 2012; Fourati et al., 2015) . The ion channel lies along the central axis of symmetry and is lined by the TM2 alpha helix (Cecchini and Changeux, 2015; Corringer et al., 2012) . The IC domain structure has been resolved in the case of the 5HT 3 receptor. It consists of a bundle of five IC helices creating a closed vestibule where lateral portals are obstructed by loops (Hassaine et al., 2014) . Orthosteric sites and channel pores are distant from each other with about 40 Å between different orthosteric sites on the same pLGIC and about 60 Å between the orthosteric site and channel pore (Herz et al., 1989) , thus making an ''allosteric organization'' that is remarkably preserved from prokaryotes to eukaryotes.
Structural analysis of rat homooligomeric GluA2 AMPA receptors (AMPARs) by X-ray (Dü rr et al., 2014; Sobolevsky et al., 2009; Yelshanskaya et al., 2014) and cryo-EM analyses (Meyerson et al., 2014 ) revealed a tetrameric organization with LGICs, which are composed of multiple subunits containing hydrophilic N-terminal regions and multiple hydrophobic M1-M4 TMD; the pore-forming M2 region is highlighted in red, and approximate location of the ECD and ICD is also indicated. (B) VGICs, which are comprised of a large, principal, a subunit and accessory b subunits. The a subunit is comprised of four domains, each consisting of six linked transmembrane segments (1-6), with the first four forming the voltage sensor, whereas segments 5 and 6 and the associated ''P loop'' contribute to the pore. (C) GPCRs, whose minimal functional unit is comprised of an extracellular N-terminal region, seven transmembrane-spanning domains (1-7) linked by three extracellular (e1-e3) and three intracellular (i1-i3) loops, and an intracellular C-terminal domain. Also shown in red is a heterotrimeric G protein.
(D) RTKs have a highly modular structure comprised of subunits containing a large ECD, a TMD linked to a JMD, and the catalytically active intracellular TKD (red). (E) NHRs also exhibit a modular structure containing an N-terminal activator function 1 (AF1) ligand independent-transactivation domain, a DBD, a variable hinge region and a C-terminal domain that contains both the LBD and the ligand-dependent transactivation domain (AF2), which co-binds co-regulators. In all instances (A-E), representative orthosteric binding domains are denoted in yellow.
symmetry properties. The subunits form a string of modular domains, beginning with the amino-terminal domain (ATD), the ligand-binding domain (LBD), which binds the neurotransmitter glutamate, and the pore-forming TMD. The ATDs and LBDs are organized as ''dimers of dimers''; the TMD exhibits $4-fold symmetry, yielding a symmetry mismatch between the LBD and TMD layers and giving rise to two non-equivalent subunit pairs, A/C and B/D (Sobolevsky et al., 2009) .
The NMDA receptor (NMDAR) (Karakas and Furukawa, 2014; Lee et al., 2014a) heterotetramer (two GluN1 and GluN2 subunits) shows a similar 3D organization as the AMPAR. An important difference lies at the level of the glutamate binding sites in the GluN1A-GluN2B heterotetrameric structure at the interface between GluN1-GluN2B heterodimers, where the LBD loop 1 0 in GluN2AR plays a major role in negative cooperativity between the orthosteric glycine-and glutamate-binding ''co-agonist'' sites (Regalado et al., 2001 ). In addition, the ATD in NMDARs contributes to the control of ion channel opening and deactivation rates and carries binding sites for allosteric modulators. Also, the TMD harbors a closed-blocked ion channel (Lee et al., 2014a ; however, see Karakas and Furukawa, 2014) , a pyramidal central vestibule lined by residues implicated in binding ion channel blockers and Mg 2+ , and a 2-fold symmetric arrangement of ion channel pore loops. Despite these receptor-specific differences, however, AMPA and NMDARs share a closely related oligomeric structure. The recent structures of two trimeric LGICs, the zebrafish P2X 4 receptor in an apo, closed, state or in complex with the agonist, ATP (Hattori and Gouaux, 2012; Kawate et al., 2009) , and the chicken acid-sensing channel 1a (ASIC1a) in a non-conducting, desensitized state (Jasti et al., 2007) or in complex with psalmotoxin (PcTx1) (Baconguis and Gouaux, 2012) revealed surprising similarities in the architecture and mechanisms utilized by these two distinct cation channels (Baconguis et al., 2013) . Both channels have six TM segments (two per subunit), short N and C termini, similar TM helical arrangements in the non-conducting states, and extracellular b sheets that ''wrap'' around 3-fold axes of symmetry (Baconguis et al., 2013) . In the agonist (ATP)-or gate-modifier (PcTX1)-bound structures, the putative orthosteric site is located at interfaces between adjacent subunits, $40 Å (ATP) or 50 Å (PcTX1) from the membrane bilayer. In short, all LGICs possess an oligomeric structure and show symmetry properties with ligand binding sites mostly at subunit interfaces.
VGICs ( Figure 2B ; 143 members in the human genome) comprise a large, channel-forming a subunit of $260 kDa and one or two b subunits of 30-40 kDa (Catterall et al., 2005a (Catterall et al., , 2005b . The structure of the a subunit of $2,000 amino acid residues from prokaryotic Na + VGIC shows four homologous domains with a 4-fold axis of pseudo-symmetry (Payandeh et al., 2011) . Each contains six TM segments (S1-S6) and an additional membrane re-entrant segment. Segments S1-S4 form the voltage-sensing module, whereas segments S5, S6, and the P loop between them form the pore. In addition to extensively studied examples of VGICs such as those of the calcium, sodium, and potassium families, the transient receptor potential (TRP) channels are symmetrical homotetramers whose 3D structure resembles that of VGICs, wherein an ion permeation pathway is formed by S5 and S6 and the reentrant pore loop region (S5-P-S6). This central pore is surrounded by four independently folded S1-S4 domains, which, in the case of VGICs, contain voltage sensors and undergo substantial movement during gating. In mammals, the TRPV1 subtype , expressed by primary afferent nociceptors, shows large IC N-and C-terminal domains, which together account for 80% of the channel's mass and mediate extensive subunit interactions. Intersubunit interactions are facilitated by discrete substructures within the cytoplasmic domain, which may regulate channel assembly and/or facilitate concerted conformational changes after co-factor binding or agonist-evoked gating.
The orthosteric activator for VGICs is voltage itself, which modulates positive gating charges at intervals of three amino acid residues in the S4 TM segment, thus defined as the ''orthosteric'' site on these channels (Catterall, 2010; Catterall and Swanson, 2015; Christopoulos et al., 2014) . This distinction is not entirely clear yet for TRP channels. Both the heat-activated TRPV1 and cold-activated TRPM8 channels are voltage sensitive (Nilius et al., 2005) ; however, voltage changes on their own are not sufficient to open the pore and require additional allosteric contributions by other potential activators, including temperature, noxious chemicals, and various lipids Liao et al., 2013) .
The largest receptor superfamily is the GPCRs (Figure 2C ), which comprise over 800 proteins in the human genome. Interestingly, these are also the receptors for which the role of oligomerization in their functionality remains controversial and are the best example of the potential existence of ''allosteric monomers.'' Structurally, GPCRs are characterized by the presence of seven TM-spanning a-helical domains connected by three intra-and three extra-cellular loops, in addition to possessing variable length extracellular N and intracellular C termini (Venkatakrishnan et al., 2013) . More than half of these GPCRs are olfactory receptors (Buck and Axel, 1991) , with the remaining GPCRs further subdivided into the class A, rhodopsin-like receptors, the class B secretin-like receptors, the class C metabotropic glutamate-like receptors, and the class F frizzled-like receptors (Perez, 2005) . GPCRs are undoubtedly ''allosteric machines'' (Christopoulos and Kenakin, 2002; Maguire et al., 1976) , since their activation mechanism involves the recognition of an extracellular signal in the orthosteric site and the transmission of the stimulus to the intracellular regions, at least $40Å away, resulting in the canonical interaction with G proteins or other transducers, such as b-arrestins (Canals et al., 2011) .
Since the turn of the millennium, there have been abundant high-resolution GPCR structural studies, in particular of class A receptors, but structures of subdomains of some class B and class C, as well as of the class F ''smoothened'' GPCR, have also been solved (Venkatakrishnan et al., 2013; Wang et al., 2013) . Most of these structures have been of inactive states, although some partial or fully active states have been solved, including rhodopsin/opsin, the b 2 adrenergic receptor and the M 2 muscarinic receptor using either G-protein-mimetic peptides or nanobodies or, in the case of the b 2 adrenergic receptor, the landmark solution of an agonist-bound, activated receptor, coupled to the nucleotide-free heterotrimeric G s protein complex (Rasmussen et al., 2011) . Some of these structures-e.g., the chemokine CXCR4 receptor (Wu et al., 2010) and the m opioid receptor (Manglik et al., 2012 )-revealed contacts proposed to contribute to dimeric interfaces, whereas the majority of other structures have not been interpreted in terms of obligate oligomeric assemblies. Nonetheless, there is evidence both for and against GPCRs naturally existing as dimers or higher-order oligomers, and this varies with the receptor type. For instance, the class A b 2 adrenergic and m opioid receptors have each been reconstituted as functional monomers in high-density lipoprotein particles and, in the presence of agonist and purified G proteins, retain their characteristic functional features (Kuszak et al., 2009; Whorton et al., 2007) . However, at the other extreme, the class C GPCRs are well validated to exist as obligate dimers and, in some cases, higher-order oligomers (Kniazeff et al., 2011) , thus confirming that these GPCRs absolutely require an oligomeric architecture. Atomic force microscopy studies of rhodopsin have also revealed an oligomeric arrangement (Fotiadis et al., 2003) . There is also a wealth of biochemical evidence of cooperativity in the actions of orthosteric ligands of both class A and class B GPCRs (Agnati et al., 2016; Bouvier, 2001; Canals et al., 2011; Smith and Milligan, 2010) , suggesting that many GPCRs participate in oligomerization as part of their functional cycle, perhaps as a means of trafficking, compartmentalization or, for those receptors that are not obligate dimers, a means of dynamically regulating their selectivity or signaling efficiency (Canals et al., 2011) .
In humans, there are 58 RTKs ( Figure 2D ) that are further subdivided into 20 families and function as receptors for polypeptide growth factors, cytokines, and related hormones (Lemmon and Schlessinger, 2010) . They all possess a variable-length, multidomain ECD that recognizes the orthosteric ligand(s), a singlepass TM region, and an intracellular juxta-membrane domain (JMD) that links to the tyrosine kinase domain (TKD), which performs the catalytic function initiating signal transduction. With a few key exceptions (e.g., the insulin receptor), most RTKs exist as monomers in the absence of ligand, but, in all instances, dimerization is part of the activation process (Ullrich and Schlessinger, 1990 ). To date, no full-length structure has been solved. At least four mechanisms, which vary by the extent to which the orthosteric ligand itself contributes to the dimerization interface, have been hypothesized for the dimerization process (Endres et al., 2014; Lemmon and Schlessinger, 2010) . These include direct cross-linking of two receptors by a bivalent orthosteric agonist, where the entire dimeric interface is provided by the ligand (e.g., nerve growth factor and its receptor TrkA; Wiesmann et al., 1999) ; the combination of both bivalent ligand and receptor interfaces to form the activating dimer (e.g., stem cell factor and its receptor, KIT; Yuzawa et al., 2007) ; the requirement of multiple contacts provided by agonist, receptor, and additional accessory proteins (e.g., FGF, heparin sulfate and the FGF receptor; Schlessinger, 2000) ; and a conformational rearrangement by the agonist to ''unmask'' an otherwise-buried dimerization arm, which then forms the entire dimeric interface (e.g., EGF binding to the EGF receptor; Burgess et al., 2003) . Given this multiplicity of hypothetical mechanisms underlying RTK dimerization, both symmetric and asymmetric arrangements of the extracellular domains have been suggested, depending on the receptor and its agonist (Endres et al., 2014; Hubbard, 1999) .
Similar considerations apply to the TK domain. High-resolution structures have identified a putatively active conformation (Huse and Kuriyan, 2002) , which requires a precise orientation of the ''activation loop'' and aC helix in the N-lobe of the TK to ensure coordination of ATP and catalysis of phosphotransfer. The key differences between RTKs with regards to the active site thus seem to arise from the transition of different inactive states to the final (common) active state (Endres et al., 2014; Hubbard, 2004; Lemmon and Schlessinger, 2010) . The EGFR family represents a special case, utilizing a separate mechanism whereby two TK domains form an asymmetric dimer in which the C-lobe of one domain interacts with the N-lobe of the second domain to remove autoinhibitory constraints in the latter (Endres et al., 2014; Lemmon and Schlessinger, 2010) .
Finally, the 48 human NHRs ( Figure 2E ) are ligand-regulated transcription factors with a conserved modular structure that comprises a disordered N-terminal domain, which contains a ligand-independent AF1 transactivation domain, a central DNA binding domain (DBD), a variable ''hinge'' region, and a C-terminal LBD that contains both the orthosteric site and a second AF2 transactivation domain, which carries the ''coregulator'' binding site (Burris et al., 2013) . The LBD of all NHRs consists of a threelayered helical sandwich with a hydrophobic pocket in which lipophilic ligands are captured and shielded from the solvent environment (Renaud et al., 1995) . However, the ligand pockets of the NHRs exhibit a wide diversity of amino acid compositions such that they accommodate a broad variety of ligands within volumes that range from $30 to nearly 1,500 A 3 (Li et al., 2003) .
It is well established that the majority of NHRs function as homo-or hetero-dimers with only a subset of monomers, including many of the orphan NHRs (Burris et al., 2013) . There have been abundant high-resolution structures of various LBDs and DBDs in different states but far fewer of complete multidomain complexes of NHRs bound to their ligands, DNA, and any associated coregulators. The X-ray structures of the full eukaryotic nuclear PPARg-RXRa (peroxisome proliferator-activated receptor-retinoid X receptor), the LXRb/RXRa heterodimers and the hepatocyte nuclear factor 4a (HNF4a) homodimer (Chandra et al., 2008 (Chandra et al., , 2013 , and the cryo-EM structure of the vitamin D receptor/ (Orlov et al., 2012) , each bound to DNA, show striking features in common, homologous to those of the much-studied bacterial transcription factor, the lac repressor (Lewis, 2005) . The DNA-bound lac repressor forms a symmetrical homodimer (Lewis, 1996) . Despite manifest sequence differences in the eukaryotic heterodimers, the relative 3D arrangements of the proteins, the domain-domain interactions, and the interfaces with DNA resemble that of the lac repressor, with a pseudosymmetrical organization around an axis perpendicular to the DNA response element. However, the homodimeric HNF-4a-DNA structure adopts a surprisingly asymmetric organization, which is also evident when the overall domain architecture of this complex is overlaid on that of the heterodimeric PPARg-RXRa-DNA (Chandra et al., 2013) .
In conclusion, a wealth of information from structural and functional studies points to oligomerization playing an important role in the function of all receptor families with the LGICs and VGICs sitting at one end of the spectrum where multimerization is essential and the GPCRs at the other.
The Allosteric Transition and Dynamics of Signal Transduction
Perhaps the most fundamental question in the field of allostery relates to the nature of the allosteric transition itself. Having established that oligomerization of these receptors is crucial for their regulatory functions, the issue then becomes understanding how changes in the complexes, both substantial and subtle, impact their operation. For pLGICs, their physiological responses are unambiguously mediated by several discrete conformations in reversible equilibrium, including resting (R), open channel (A), slow (D), and fast (I) desensitized states (Changeux and Edelstein, 2005; Katz and Thesleff, 1957) . Recent structural and computational studies of GLIC ( Figure 3A) , ELIC, and GluCl consistently point to a model of channel gating that follows a progressive stepwise isomerization (or conformational wave) that starts from the orthosteric binding site, propagates to the EC/ TM domains interface via a rigid-body rearrangement of the extracellular b sandwiches, and moves down to the TM helices to ultimately open the gate (Calimet et al., 2013; Grosman et al., 2000; Purohit et al., 2007; Sauguet et al., 2014) . It involves a sequence of two distinct quaternary transitions ( Figure 3B ). First, a radial contraction or (un)-blooming of the EC domain, as a large radial reorientation or tilting of the extracellular b sandwiches that promotes the opening of the ion pore (Althoff et al., 2014; Calimet et al., 2013; Nury et al., 2010; Sauguet et al., 2014) , followed by a global un-twisting of the receptor, best described by a concerted opposite-direction rotation of the ECD relative to the TMD about the 5-fold symmetry axis, to lock the channel in its active state (Althoff et al., 2014; Bocquet et al., 2009; Calimet et al., 2013; Dutzler, 2008, 2009; Nury et al., 2010; Sauguet et al., 2014; Taly et al., 2005) . These ''twist and bloom'' transitions mediate the dynamic reorganization of the interfaces between subunits, which host several binding sites (see below).
Additional recent studies, in agreement with the stepwise model of channel gating, offer new insights on the transitions to desensitized states that follow the opening of an ion channel. An ELIC closed channel structure (Hilf and Dutzler, 2008 ) is consistent with a desensitized D state, with a profound quaternary reorganization of the ECD together with a different configuration of the ion pore (Sauguet et al., 2014) . Similarly, the recently identified structure of the eukaryotic GABA A b 2 homopentamer is consistent with a D state. A ''locally closed'' state of GLIC exhibits the conformation of the active state but with a closed channel and plausibly corresponds to an I, fast-desensitized (Prevost et al., 2013) or intermediate (Lape et al., 2008) state. Thus, with an increase in structural models for discrete conformational channel states, a mechanistic understanding of the transitions between them is now becoming accessible. Comparison of the structures of the AMPAR by X-ray crystallography (Lee et al., 2014a) , EPR spectroscopy, and cryoEM (Dü rr et al., 2014) in resting, active, and desensitized states reveals that transitions occur in the LBD clamshell and within the LBD dimer but also between LBD dimers and the ATD. AMPAR activation upon agonist binding to the apo/resting state occurs with an intact D1-D1 LBD dimer interface, enhancing the probability that domain closure in response to agonist is conveyed to separation of the D2 lobes within a LBD dimer. Accompanying the conformational changes within LBD dimers is a rotation and translation of LBD dimers, thus resulting in a separation of the LBD D2 lobes, pulling open the ion channel gate at or near the M3 bundle crossing. Orthosteric agonist binding conveys a clamshell closure to channel opening, while antagonists stabilize the cleft in a more ''open'' conformation. Under nondesensitizing conditions, the LBDs are organized as back-to-back dimers, and perturbations that weaken the dimer interface enhance receptor desensitization. In conclusion, as with pentameric LGICs, AMPARs undergo concerted changes of quaternary organization of the molecule upon activation and desensitization.
For the trimeric P2X and ASIC1a channels, the key steps in the allosteric transition are proposed to be an agonist-promoted outward movement of the TM domains lining the channel pore that is mediated by flexible b strands linking the (relatively rigid) amino terminal orthosteric ligand-binding domain to the channel (Baconguis et al., 2013) . In the case of the P2X4 receptor, the transition involves a relatively simple ''iris-like'' rotation and pore expansion that maintains symmetry, whereas the movements within ASIC1a are qualitatively different because they are sensitive to pH state, retaining symmetry at low pH but becoming asymmetric at high pH (Baconguis and Gouaux, 2012) . In summary, these data are consistent with the general view that LGIC interfaces between subunits play a critical role in the allosteric transition.
For VGICs, early kinetic studies suggested that voltage sensor activation involves a concerted transition that opens the central ion pore (Kuzmenkin et al., 2004; Zagotta et al., 1994; Zhao et al., 2004) , consistent with a MWC mechanism. The recent crystal structure of the voltage-gated Na + channel from Arcobacter butzleri (NavAb) is in accord with this model, revealing a ''preopen'' state in which all four voltage-sensing S4 domains are simultaneously activated, in essence ''poised'' to propagate a concerted opening of the channel pore via the S4-S5 linker (Payandeh et al., 2011) , which is ultimately known to be transmitted to the pore-lining S6 segments (Catterall et al., 2007) . Interestingly, however, cryo-EM studies with the TRPV1 channel reveal differential gating mechanisms for TRPs compared to other VGICs by capturing protein structures in distinct conformations . Regions targeted by proalgesic inflammatory agents stabilize conformational changes associated with gating. These regions include the outer pore domain, which is unusually dynamic compared to typical VGICs, as well as the hydrophobic pocket defined by the external surface of the S3-S4 helices, S4-S5 linker, and S6 helix, thus exerting effects on either of two restriction points defined by the selectivity filter and lower gate.
In the case of GPCRs, the best-studied and conceptually most straightforward model is that of rhodopsin, which, despite proceeding through a series of very short-lived intermediate states, displays an almost ''switch-like,'' two-state behavior in going from the fully inactive dark rhodopsin (which is pre-bound to the endogenous inverse agonist, 11-cis-retinal) to the fully alltrans-retinal bound active metarhodopsin II (Deupi et al., 2012) . The characteristic features of the allosteric activation transition for monomeric GPCRs begin with a ''pulling'' of the extracellular sides of TMs 3, 5, and 7 (essentially contracting the orthosteric binding pocket for hormone GPCRs) or an increased volume of the retinal binding pocket in rhodopsin. Both instances then result in a rearrangement of highly conserved hydrophobic and aromatic residues deeper in the receptor core (the ''transmission switch'') to ultimately result in the most dramatic change upon activation, a 6-14 Å (depending on the receptor) rotation and outward rigid body displacement of TM6 ( Figure 3C ), as well as additional rearrangements of TMs 5 and 7 in the cytoplasmic region, thus opening the interface for interaction with the G protein (Venkatakrishnan et al., 2013) .
Interestingly, there are numerous active state structures of metarhodopsin II with and without a peptide corresponding to the C terminus of the Ga subunit of the G t protein that are very similar, indicating that the two key states of rhodopsin (inactive versus fully active) are highly stable in their own right and represent preferred lowest energy conformations, in agreement with the original MWC (Manglik and Kobilka, 2014) . Studies of the partial and fully active states of the hormone class A GPCRs solved to date indicate that the complete transition to the fully active state requires stabilization by the presence of both agonist and G protein, G-protein-mimetic (e.g., conformationally selective nanobody), or other transducer protein (DeVree et al., 2016) . This need for dual interactions on the same receptor is still globally consistent with the occurrence of discrete allosteric states Lamichhane et al., 2015) ( Figure 3D ) but might possibly involve a broader dynamic sampling of functionally relevant conformational substrates.
It should be noted that less is known about the allosteric transitions in other classes of GPCRs. NMR and crystallographic studies have thus far only provided atomic-level details on isolated domains of class B and C GPCRs-e.g., the N-terminal domains versus the TM domains (Venkatakrishnan et al., 2013) . Interestingly, for the class C dimeric mGluR GPCRs, examination of partial domain crystal structures, combined with elegant structure-function and spectroscopic and computational methods, supports a complex multi-step model, whereby the transition is triggered by the binding of orthosteric agonist to the ''venus flytrap (VFT)'' N-terminal lobe of the promoters, leading to VFT closure and consequent reorientation of the two lobes in a ''scissor-like'' movement that brings the attached extracellular linker domains closer together, which then causes a rearrangement of the 7TM regions of the dimer to asymmetrically activate the G protein (Rondard and Pin, 2015) .
In terms of transcription-factor allosteric transitions, the X-ray structures of the lac repressor in the induced and the repressed states reveal that the orientations of the subdomains change through a small hinge motion of the N-terminal subdomain relative to the C-terminal subdomain (with little, if any, change of tertiary structure) while preserving the 2-fold axis of the dimer. This conformational change links the effector site, through the dimer interfaces, to the hinge helices and the DNA-binding domains. Binding of the inducer stabilizes a subtle structural change in the N-terminal subdomain, which is sufficient to destabilize the repressor-operator complex and reduce the repressor's affinity for the operator by several orders of magnitude, thus triggering the genetic switch. The overall data are quantitatively fitted by the MWC model (Lewis, 2005) .
However, structural information concerning the allosteric transition in human NHRs is still limited at this stage to isolated domains, in particular the LBD and DBD. Nonetheless, the basic mechanism is clearly established and involves the encapsulation of the orthosteric ligand within the hydrophobic LBD, receptor dimerization and interaction of the DBD with nuclear response elements, recruitment of coregulatory proteins, and association with transcription initiation complexes (Burris et al., 2013) . Numerous studies utilizing crystallography of apo and holo structures of the LBD, as well as hydrogen/deuterium exchange (HDX) and NMR, have highlighted a pivotal role for movement of the C-terminal helix 12 (H12) in the LBD in both the opening-closing of the orthosteric pocket and the subsequent formation of the AF2 coregulator binding surface, which represents the key allosteric transition within the LBD of the NHRs (Mackinnon et al., 2014) . Interdomain allosteric communication is also critical for these receptors, as highlighted particularly by the PPARg/ RXRa and HNF-4a crystal structures bound to their DNA response element (Chandra et al., 2008; Chandra et al., 2013) and also by studies showing how response elements can modulate orthosteric ligand and coregulator binding, how allosteric effects can be propagated between the LBD and DBD, and through the computational identification of energetically preferred communication ''pipeline'' residues that have coevolved to link different surfaces across NHRs (Hall et al., 2002; Meijsing et al., 2009; Shulman et al., 2004) .
Similarly, with a lack of complete high-resolution structures of human RTKs in different states, the mechanisms governing allosteric transitions within these receptors remain an area of intense research. Even though it is well acknowledged that the formation, or reorganization, of dimeric interfaces is necessary for RTK activation, more recent studies indicate that the extracellular RTK domains can be directly coupled allosterically to mediate activating conformational changes to the TK domain across the plasma membrane, involving active reorganization of both the TM helices and the juxtamembrane region (Endres et al., 2014) . A striking illustration of this mechanism was proposed through structural and long-timescale MD simulations that present a model of how full-length inactive EGFR monomers can first associate into symmetric (but still inactive) dimers and how the subsequent binding of orthosteric ligand can actively reorganize the TM and juxtamembrane regions to remove a steric block to formation of the active state, which is then ultimately completed by asymmetric TK domain assembly Endres et al., 2013 ).
An important postulate of the allosteric transitions within the MWC model is the spontaneous occurrence of several conformations-at least two-in reversible equilibrium in the absence of ligand. A variety of biophysical techniques applied to studies of LGICs (Cecchini and Changeux, 2015) , GPCRs (Canals et al., 2011) , RTKs (Lemmon and Schlessinger, 2010) , and, at a more preliminary stage, to NHRs (Didenko et al., 2013; Sharon and Horovitz, 2015; Manglik and Kobilka, 2014; Nussinov and Tsai, 2014) have now unambiguously confirmed this concept for receptors, with the extension of this notion to multi-state ensembles that are redistributed by the binding of ligand (Cui and Karplus, 2008; Changeux 2013a; Motlagh et al., 2014; Nussinov and Tsai, 2014; Weber, 1972) . The data presently available in these diverse systems strongly support a conformational selection scheme rather than any induced-fit mechanism elicited by ligand binding.
Constitutive Mutations and Receptor Diseases
An important prediction of the MWC model is that the shift of the spontaneous equilibrium between active and inactive conformations by mutations, causing loss or gain of function, might be associated with disease states (Changeux, 2013a) . More than 1,000 activating and inactivating mutations in both LGICs and VGICs show that full channel openings may take place spontaneously and with high frequency in the absence of agonist. These mutations lead to diseases that include congenital myasthenia and autosomal dominant nocturnal epilepsy, hyperplexia, ataxia, and cardiac arrhythmias, including the ''long-QT syndrome'' (Hü bner and Jentsch, 2002; Steinlein, 2012) . In the case of pLGICs, these mutations are preferentially located either at the interface between subunits or within a given subunit at the interface between rigid domains of the receptor protein (Taly et al., 2006) , again highlighting the key role of oligomeric architecture on the function of allosteric proteins in both physiology and disease.
The overexpression of RTKs in the plasma membrane is well known to contribute to pathologies such as cancer due to inappropriate activation as a consequence of ligand independent dimerization (Endres et al., 2014; Zwick et al., 2001) . Similarly, naturally occurring mutations in RTKs increase catalytic activity and result in various clinical phenotypes (Blume-Jensen and Hunter, 2001; Hubbard, 2004) . Mutations that disrupt key components of the allosteric transition in NHRs, such as ligand binding, dimerization and the ability to bind DNA, have been implicated in cancer, metabolic dysfunction, and sexual and developmental disorders (Tenbaum and Baniahmad, 1997) .
Hundreds of gain-or loss-of function mutations have been identified in GPCRs (Tao, 2008; Vassart and Costagliola, 2011) . The mutations cause diseases such as retinitis pigmentosa, autosomal dominant hypocalcemia, hyperthryroidism, malelimited precocious puberty, familial short stature, and even some forms of obesity (Tao, 2008; Vassart and Costagliola, 2011) . Several of them change the basal activity of the receptor, which can be restored to the ''resting activity'' by the use of positive or negative allosteric modulators, depending on the context (Leach et al., 2015) . These observations clearly highlight the potential for pharmacotherapeutic approaches to correct for the inappropriate functionality of mutated (or overexpressed) receptors.
The Phenomenon of ''Biased Agonism''
The concept of ''biased agonism''-i.e., the ability of a ligand to stabilize distinct conformations of a given receptor such that only a subset of the possible signaling pathways mediated by that receptor are engaged, to the relative exclusion of other pathways-was first explicitly defined in studies of GPCRs (Kenakin, 1995; Kenakin and Christopoulos, 2013) . For example, Azzi et al. (2003) demonstrated that previously classified ''beta-blockers'' (i.e., clinically used competitive antagonists of the b 2 adrenergic receptor) could actually activate the MAP kinase pathway as agonists in a b-arrestin-dependent but G-protein-independent manner, thus highlighting the potential for the occurrence of multiple active conformations that differentially recognize transducers. This phenomenon was extended to various classes of GPCRs (Violin and Lefkowitz, 2007) , and biased agonism now represents a major paradigm in GPCR drug discovery (Kenakin and Christopoulos, 2013) . The same phenomenon may exist in even earlier studies of NHRs, specifically in the context of compounds termed ''selective NHR modulators,'' with tamoxifen being a prototypical example at the estrogen receptor (Burris et al., 2013; Jordan, 2007) . This drug demonstrates either pro-estrogenic or anti-estrogenic actions in a tissue-specific manner, thus being the first example of a ''selective estrogen receptor modulator.''
The simplest allosteric mechanism to account for biased agonism requires the existence of at least two-instead of one-active states, each possessing different agonist-binding specificities and signal transduction properties (Galzi et al., 1996a; Leff et al., 1997; Edelstein and Changeux 2010) . This view is consistent with the broader notion of multi-state ensembles that are redistributed by orthosteric or allosteric ligands binding not exclusively to one state but to several states with different affinities (Rubin and Changeux 1966) . Studies employing 13 CH 3 ε-methionine and 19 F-NMR spectroscopy to look at the conformational landscape of the b 2 adrenergic receptor have revealed highly dynamic changes at both the extracellular and intracellular faces, consistent with the exploration of different conformational ensembles by ligands (Bokoch et al., 2010; Liu et al., 2012) . Interestingly, the recent solution of the first crystal structure of a constitutively active form of rhodopsin bound to a pre-activated visual arrestin revealed substantial conformational differences in TM domains 1, 4, 5, and 7, in addition to the canonical movement of TM6 observed in the G-protein-binding state (Kang et al., 2015) , consistent with the notion that different GPCR transducer proteins (e.g., b-arrestin versus G protein) stabilize structurally distinct active states. The extent to which biased agonism has been explored at other receptor families beyond the GPCRs and NHRs remains unclear, but the ability of all receptors to undergo multiple allosteric transitions suggests that the phenomenon is likely widespread (Ellis et al., 2007; Rowlinson et al., 2008; Suh et al., 2014) .
The Contributions of ''Intrinsic Disorder'' to Receptor Allostery A major paradigm shift in the 1990s about the relationship of the amino acid sequence of a protein to its 3D architecture was the recognition that many eukaryotic proteins commonly contain regions that are intrinsically disordered (Dunker et al., 1998 (Dunker et al., , 2008 Wright and Dyson, 2015) and dynamically fluctuate through disorder-to-order transitions. The occurrence of intrinsic disorder is now thought to provide a means of maximizing allosteric coupling in many protein families (Eginton et al., 2015; Hilser and Thompson, 2007; Motlagh et al., 2014; Simon et al., 2014) . The idea is that the absence of a unique ''rigid'' conformation confers a plasticity that readily supports dynamic changes in response to changing local environments, including protein or ligand binding. Intrinsically disordered regions have been identified in all classes of plasma membrane receptors, predominantly (although not exclusively) within cytosolic regions (Minezaki et al., 2007) . Changes in order-to-disorder organization (or vice versa) have been proposed as key mechanisms underlying the allosteric modulation of G protein activation and potentially b-arrestin interaction with GPCRs (Flock et al., 2015; Shukla et al., 2013) , as well as the activation of the EPHB2 RTK (Hubbard, 2004; Shan et al., 2012; Wybenga-Groot et al., 2001 ). Arguably, however, the best example of the role of intrinsic disorder in receptor functionality is seen with NHRs. The N-terminal domain of NHRs, which contains the AF1 region, shows a high degree of intrinsic disorder. This region is often more transcriptionally active than the better structurally characterized LBD AF2 region (Simons et al., 2014) . Given such intrinsic disorder, no common motif has yet been defined for coregulator binding proteins that interact with AF1. NHR N-terminal domains contain most of the phosphorylation sites for post-translational modifications (Hill et al., 2012 ) and thus play a major contribution to the overall conformational dynamics that govern allosteric transitions between NHR domains. Post-translational modifications may influence the allosteric transition mediated by NHRs, as classically observed with eukaryotic regulatory enzymes like phosphorylase b (Fischer, 1992) and many receptors (see above).
Allosteric Modulatory Sites and Their Pharmacology
Since the early discovery of benzodiazepines as GABA A receptor allosteric activators, it was shown that most, if not all, cellular receptors possess, in addition to the orthosteric site, spatially distinct sites that modulate their allosteric transitions (Changeux, 2012; Christopoulos et al., 2014; Figure 5) . Pharmacologically, allosteric ligands can be classed as ''positive allosteric modulators'' (PAMs), which enhance the effect of the orthosteric ligand, ''negative allosteric modulators'' (NAMs), which reduce the effect of the orthosteric ligand, and ''neutral allosteric ligands'' (NALs), which occupy the allosteric site but do not modulate the effect of orthosteric ligand. A PAM may sometimes activate the receptor in the absence of agonist and is then referred to as an ''allosteric agonist'' . Combinations of these properties are also observed (Keov et al., 2011) . Allosteric Sites on LGICs Several allosteric sites have been identified in pLGICs (Changeux, 2012; Sauguet et al., 2014) , from ECD interfaces to the TMD and, potentially, the cytoplasmic face. For instance, Ca 2+ ions bind as PAMs in the ECD at the interface between subunits close to the TMD of a7 and a4b2 nAChRs (Galzi et al., 1996b; Le Novè re et al., 2002; Mulle et al., 1992; Vernino et al., 1992) . Ba 2+ binds as a NAM to a similar site on ELIC (Zimmermann and Dutzler, 2011), and GLIC shows a homologous pocket (Sauguet et al., 2014) . Given that most pLGICs are heterooligomers, the potential for non-agonist-binding ECD interfaces to harbor hitherto-unappreciated modulatory sites was predicted to be a likely general feature in such receptors (Galzi and Changeux, 1994) , and the best clinically validated examples of this are the benzodiazepines, which indeed bind as PAMs to a non-agonist ECD interface in the GABA A receptor (Sawyer et al., 2002; Smith and Olsen, 2000) .
In contrast, the anthelminthic PAM, ivermectin, binds within the a7nAChR TMD (Krause et al., 1998) , as do synthetic PAMs, such as PNU-120596 and LY2087101 (Bertrand and Gopalakrishnan, 2007; Chatzidaki and Millar, 2015) . In the GLIC structure, the general anesthetics (GAs), isoflurane and propofol, bind in the upper half of the TMD that is accessible from the lipid bilayer (Nury et al., 2011 ). An ivermectin site (Figure 4 ) is also seen in the GluCl structure (Hibbs and Gouaux, 2011) in the periphery of the TMD at sub- Shown are the homopentameric Caenorhabditis elegans glutamate-gated chloride channel (GluCl) (PDB: 3RHW), where the allosteric modulator, ivermectin, sits within the transmembrane regions of the channel; the human M 2 mAChR (PDB: 4MQT), where the allosteric modulator, LY2119620, sits within the extracellular vestibular entrance to the receptor, above the orthosteric agonist, iperoxo; the rat NMDA R (PDB: 4PE5), where the allosteric modulator, ifenprodil, is located at interfaces between amino terminal domain subunits, whereas the orthosteric co-agonists, L-glutamate and glycine, sit within the ligand binding domain. unit interfaces. The intersubunit TMD cavity is conserved in human glycine and GABA A receptors, involving residues that influence ethanol and anesthetic action (Li et al., 2006; Olsen, 2014; Sauguet et al., 2013) . Computational analyses of the cryo-EM structure of the Torpedo nAChR (Brannigan et al., 2008 ) and a homology model of the GABA A receptor (Hé nin et al., 2014) show the existence of several TMD cavities complementary to cholesterol and possibly homologous to the ivermectin site in GluCl. Cholesterol binding at these sites would stabilize the channel open-pore conformation, suggesting a role (together with lipids in general) as putative endogenous allosteric modulators in eukaryotic pLGICs.
Finally, in addition to the ECD and TMD allosteric modulator sites, the IC domain represents another potential region for allosteric modulation of pLGICs-e.g., by post-translational modifications and interaction with scaffolding proteinsbut remains the least pharmacologically explored (Changeux, 2013b; Hassaine et al., 2014) .
For the non-pLGIC NMDARs, the majority of allosteric sites have been localized to the ATD (Traynelis et al., 2010; Zhu and Paoletti, 2015) and bind divalent cations, such as Zn 2+ and Mg
2+
, endogenous polyamines (e.g., spermine and spermidine) and various synthetic modulators, such as ifenprodil (Figure 4) , which bind at the interface between two ATDs (Karakas et al., 2011) . Tentatively, any ligand that stabilizes the ATDs in an open-cleft configuration may behave as a PAM, while a ligand promoting ATD cleft closure acts as a NAM.
More recently, allosteric NMDAR modulators have been identified within the vicinity of the LBD, typified by compounds such as TCN-201, DQP-1105, UPB512, and QNZ46 (Zhu and Paoletti, 2015) . Less is known about the potential for allosteric sites in the TMD or intracellular domains of the NMDAR, although it has been suggested that the small molecule, CIQ, and the endogenous neurosteroid, pregenolone sulfate, are PAMs via the TMD (Zhu and Paoletti, 2015) . In contrast to the NMDAR, the LBD of the AMPAR appears to be the major site for allosteric modulators, including the ions Cl À and Na + , as well as synthetic PAMs that include aniracetam, cyclothiazide, and biaryl propylsulfonamides (Partin, 2015) . Last but not least, recent structural and dynamic studies with LGICs demonstrate that, in agreement with their differential effects on the allosteric equilibrium, the structure(s) of allosteric modulatory site(s) differ between resting and active states. For example, a close comparison of the X-ray structures of active and resting conformations in GLIC (Sauguet et al., 2014) and MD simulations with GluCl (Calimet et al., 2013) reveal that, during activation in GLIC, a tertiary change significantly reshapes the subunit interface and the binding pocket homolog of the PAM Ca 2+ site and that, in GluCl, removal of ivermectin from its TM site shrinks substantially by receptor twisting (Sauguet et al., 2014) . This observation has important consequences for the design of allosteric modulatory drugs.
Allosteric Sites on VGICs
There is a rich repertoire of neurotoxins and drugs that bind allosterically in VGICs. For sodium channels (NaV), there are at least six distinct sites of neurotoxin action, as well as a site for local anesthetics (LAs) (Cestè le and Catterall, 2000; Christopoulos et al., 2014) . LAs bind within the central pore cavity as blockers, whereas tetrodotoxin and m-conotoxins bind to the outer pore opening. Scorpion toxins modulate voltage-dependent gating by binding to the extracellular ends of the S3-S4 voltage sensor (Catterall and Swanson, 2015) , while lipophilic toxins (e.g., batrachotoxin) bind within the TMD of the S5-S6 regions (Cestè le and Catterall, 2000) . For L-type voltage-gated Ca 2+ channels (CaV), there are at least three allosterically coupled sites targeted by marketed drugs (Spedding, 1985a (Spedding, , 1985b Spedding and Berg, 1984; Striessnig, 1999) such as phenylalkylamines (e.g., verapamil) or benzothiazepines (e.g., diltiazem), which act within the pore, or dihydropyridines (e.g., amlodipine), which act as gating modifiers (Table 1 ). There are also neurotoxins, such as u-conotoxin GVIA and u-agatoxin IVA, which act as pore blockers or gating modifiers, respectively . Spiders produce a multitude of peptide toxins that activate TRPV1 to elicit pain as part of the spider's chemical defense mechanism. One such vanillotoxin (called ''double-knot toxin,'' DkTx), traps TRPV1 in its open state with near-irreversible kinetics through attachment within the S5-P-S6 pore region, consistent with the notion that the outer pore of TRPV1 is conformationally dynamic and contributes directly to gating .
Allosteric Sites on GPCRs
Most GPCRs possess at least one, if not more, allosteric modulatory sites (Christopoulos, 2014; Gentry et al., 2015) . Furthermore, two GPCR allosteric modulators, maraviroc (CCR5 NAM) and cinacalcet (calcium-sensing receptor PAM), are on the market . The majority of synthetic GPCR allosteric modulators identified to date bind within the TMD region, but the location within the TMD cavity can vary dramatically depending on the receptor class. This variability is due to the high degree of both sequence and tertiary structure divergence in the orthosteric domain for these receptors (Conn et al., 2009; Gentry et al., 2015) . An important finding contributing to understanding the structural basis of GPCR allosteric modulatory sites was the solution of two crystal structures of an active M 2 muscarinic receptor, concomitantly bound to an orthosteric agonist and a G protein mimetic nanobody and either the absence or presence of the small molecule PAM, LY2119620 (Figure 4 ; Kruse et al., 2013) . These two structures clearly delineated the allosteric transition between active and inactive states but also revealed very little difference in the allosteric pocket in the absence or presence of the PAM . This comparison suggests that the modulatory site is ''pre-formed'' upon transition to the active state, a mechanism consistent with a MWC scheme whereby the effect of the PAM is to preferentially stabilize this state (Kruse et al., 2014) . It remains to be seen how generalizable the above mechanism is. Interestingly, mutagenesis studies have also identified putative intracellular allosteric sites for synthetic modulators of some chemokine receptors, and novel lipidated peptides (''pepducins'') have been designed to specifically modulate the intracellular surfaces of different GPCRs (Gentry et al., 2015) . Finally, it is worth highlighting that there remain numerous pharmacological examples of GPCRs that display cooperativity in their modes of interaction with both cognate and synthetic ligands, suggesting that the potential for interactions across GPCR oligomeric arrays is also possible (Agnati et al., 2016; Bouvier, 2001) . Allosteric Sites on RTKs Although the catalytic TK domain has traditionally represented the major focus of small molecules targeting RTKs, there are no examples yet of pure allosteric modulators for this region; all clinically used small-molecule inhibitors of the TK domain of RTKs are ATP-site competitive to some extent (De Smet et al., 2014; Fabbro, 2015) . Better clinical examples of allosteric targeting of RTKs involve the ECD, particularly with antibodies. For instance, although most ECD-directed antibody strategies target the orthosteric ligand or its binding site (Hicklin et al., 2001) , the clinically used trastuzumab (Hereptin) and pertuzumab (Perjeta) target domains 4 and 2, respectively (Table 1) , of the HER2/neu RTK to inhibit functionality either through promoting receptor downregulation (trastuzumab) or preventing dimerization (pertuzumab). Neither one of the RTK binding domains recognized by these antibodies constitutes the orthosteric site Franklin et al., 2004) , so the clinical effects of both agents are likely allosteric. Other allosteric RTK antibodies have been discovered, such as XMetA and XMetS, which bind to the ECD of the insulin RTK and activate the receptor or act as an insulin-sensitizing PAM (Bhaskar et al., 2012; Corbin et al., 2014) . Allosteric ECD interactions have also been identified at RTKs mediated by peptidomimetics (De Smet et al., 2014) . Most recently, the first ECD small-molecule RTK inhibitor was identified ( Figure 5 ). SSR128129E interacts with the D2D3 domain of multiple FGFRs to inhibit hormone signaling in a clearly allosteric manner (Bono et al., 2013) . Finally, a lesscharacterized RTK target is the juxtamembrane/TM region. However, recent work from Jang et al. (2007) identified an allosteric agonist, gambogic amide, which selectively binds to this region of the TrkA RTK.
Allosteric Sites on NHRs
There is no current consensus on the importance of targeting allosteric modulator sites on NHRs (Hughes et al., 2014) . Furthermore, virtually all clinically relevant targeting of NHRs to date has been via orthosteric drugs (Burris et al., 2013) . Nonetheless, ''alternate'' pockets distinct from the orthosteric site have been identified in some (Burris et al., 2013; Hughes et al., 2014; Moore et al., 2010) . The extent to which these sites unambiguously modulate orthosteric ligands remains largely undetermined, however, and we thus refer to them as ''putative allosteric sites.'' There are at least five potential alternate binding surfaces on NHRs (Figure 5 ). The best-studied is the AF2 coregulator site (Arnold et al., 2005; Kojetin et al., 2008; Moore et al., 2010 ). LBD pocket in the PPARg receptor that binds synthetic molecules concomitantly to the orthosteric site. Other molecules have been described that interact with nuclear response elements and with zinc fingers in the DBD, such as the estrogen-receptor-targeting compound DIBA (Moore et al., 2010) . Finally, at least one small molecule that blocks transactivation of the androgen receptor, EPI-001, interacts within the intrinsically disordered AF1 region (Andersen et al., 2010) .
Although the pursuit of allosteric modulators of NHRs remains a nascent field for drug discovery, recent studies of non-hormone transcription factors have identified synthetic modulators aimed at targeting the transcription factor dimeric interface. One such example is a series of small molecules targeting the OLIG2 transcription factor, which show promise as potential inhibitors of glioblastoma (Tsigelny et al., 2015) .
Concluding Remarks Allosteric Interactions in Receptors
Abundant structural data show that the original concept of allosteric interactions as indirect interactions established between Data collated from the Thomson Reuters Cortellis Database, using the search term ''allosteric,'' followed by manual inspection and literature-based validation of mechanism of each entry by the authors. The only exceptions were trastuzumab and pertuzumab, the mechanism of which was taken from Cho et al. (2003) and Franklin et al. (2004) . ''PAM'' denotes ''postitive allosteric modulator'' and ''NAM'' denotes ''negative allosteric modulator.'' topographically distinct sites and mediated by a discrete protein conformational change successfully applies to signal-transducing receptors. The signal transduction mechanism mediated by these receptors, in many instances, occurs in agreement with the MWC model via the selective stabilization by ligands of a few (frequently more than two) pre-existing discrete states in conformational equilibrium. Organization into symmetrical oligomers, a feature that was initially proposed to specify the cooperativity of the structural transition that mediates cooperative ligand binding, is also found in many receptor categories. Yet, several well-documented cases have been described, typified by the GPCRs, in which signal transduction takes place in non-oligomeric structures, nevertheless, via pre-existing conformational states.
In several receptor systems, in particular LGICs and GPCRs, the conformational change engaged in the signal transduction mechanism has been resolved at the atomic scale. In the case of pLGICs, it includes a stepwise quaternary change that includes blooming and twisting with reorganization of the interfaces between subunits, which host orthosteric and allosteric binding sites (Figure 4) . In GPGRs, the conformational transition involves an inward contraction of the extracellular regions of the TMD that is propagated as an outward opening of the intracellular domains to expose the interface for transducer binding. Although complete atomistic details remain to be resolved for other receptors, it is worth noting that oligomerization, cooperativity, and long-range conformational changes mediated through allosteric transitions have been demonstrated for other classes of receptors, such as the cell-adhesion-mediating integrin receptors and the pathogen-targeting pattern-recognition (e.g., Toll-like) receptors (Arnaout et al., 2005; Gay et al., 2014; Hynes, 2002; Schü rpf and Springer, 2011) , further highlighting the universality of the allosteric transition mechanism.
Finally, it is worth noting that the allosteric concept, as applied to regulatory proteins and now receptors, can also be extended to even larger protein assemblies (Changeux et al., 1967; Changeux, 2013a) , creating important functional links between the molecular and cellular levels through large-scale allosteric transitions. This represents fertile ground for future studies of ''supramolecular'' protein assemblies. Shown schematically are different regions that have been proposed to interact with allosteric modulator ligands for LGICs, VGICs, GPCRs, RTKs, and NHRs, including representative examples for each of the sites (where validated; otherwise, they are referred to as ''putative'' allosteric sites). Note, for ion channels, black circles denote sites of interaction for molecules that directly interact with the endogenous agonist site(s) or sterically hinder the channel. For GPCRs, the nature/ location of the orthosteric site vary with the class of GPCR (A, B, C, or F). ATD, amino terminal domain; RE, response element. All other abbreviations as defined in the legend for Figure 2 .
Toward a New Pharmacology Until relatively recently, drugs were classically designed following the concept of direct competitive interactions between ligands for a common ''rigid'' site (Bovet, 1964; Black, 1989) . The discovery of the intrinsic flexibility of allosteric proteins, and of allosteric modulatory sites on all classes of receptor (Figure 5 ), supersedes the notion of ''rigid site'' pharmacology and opens the field to the design of new categories of ''conformation-specific'' drugs that interact a`distance with topographically distinct active sites. This concept applies to both orthosteric ligands and allosteric modulators because the binding pockets for either class concomitantly change between states during the allosteric transition that underlies receptor signal transduction (Cecchini and Changeux, 2015; Sauguet et al., 2014; Taly et al., 2009 ). However, a specific advantage of targeting allosteric modulator sites over orthosteric sites is that the former can exhibit a higher degree of sequence diversity between receptor subtypes, thus providing a degree of selectivity in receptor targeting that is simply unattainable with many orthosteric agonists/antagonists (Changeux, 2013b; Gentry et al., 2015) . It should also be noted that allosteric targeting need not be achieved solely through the design of synthetic small molecules but also can also be reached via conformationally specific allosteric antibodies, which represents an important field of future research. There are already clear examples of monoclonal antibodies that allosterically target ion channels (Lee et al., 2014b) , GPCRs (Mukund et al., 2013) , and RTKs (De Smet et al., 2014) , as well as cytokine and integrin receptors (Rizk et al., 2015; Schwarz et al., 2006) . However, because allosteric modulators can display a diverse spectrum of effects, usually in a ''context-dependent'' manner , traditional biochemical approaches are suboptimal for studying such molecules, and functional screening methods are still being developed to maximize the detection of allosteric effects (Wootten et al., 2013) . Furthermore, as discussed above, most receptors are oligomers, and thus their subunit assembly and stoichiometry can have a dramatic effect on screening for allosteric modulator activity (Taly et al., 2009) . Finally, it is important to note the potential for endogenous allosteric substances that may play important roles in both health and disease (van der Westhuizen et al., 2015) .
Such drug discovery challenges can be better addressed as more structural data on allosteric sites and transitions become available. Interestingly, at the time of writing, a curated online ''allosteric database'' (Huang et al., 2011) classifies nearly 72,000 substances as allosteric modulators (http://mdl.shsmu. edu.cn/ASD/), which attests to the ongoing growth and interest of the phenomenon and even allows one to envisage the concept of an ''allosterome'' as a valuable resource for new chemical, cellular, molecular, and structural biology breakthroughs. As highlighted by the selected examples in Table 1 , there is already clear evidence for success in allosteric pharmacology for receptors and enzymes.
In conclusion, it is now clear that substantial opportunities exist for allosteric targeting of all receptor families. This is a critical pursuit because allosteric medicines have the potential to display conformation-and site-based selectivity, pathophysiologically relevant ''context-sensitivity,'' and greater mechanism-based on-target safety than traditional orthosteric activators or blockers. Despite being recognized over 50 years ago, the concept of allosteric interaction, as illustrated in this Review, continues to blossom with its extension to all receptors and is yielding new and fertile avenues for research across the life sciences.
